Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the sale, the insider now directly owns 299,441 shares in the company, valued at approximately $34,082,374.62. The sale was disclosed in a document filed with the SEC, which is available at this link.
Jonathan Sheena also recently made the following trade(s):
- On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $108.87, for a total value of $293,949.00.
- On Tuesday, June 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $109.66, for a total value of $296,082.00.
- On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $108.30, for a total value of $108,300.00.
Natera Trading Down 0.4 %
Shares of Natera stock traded down $0.52 during trading on Wednesday, reaching $118.50. 830,494 shares of the company were exchanged, compared to its average volume of 1,401,661. The company has a quick ratio of 3.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $119.90. The business has a 50-day moving average price of $108.46 and a 200-day moving average price of $96.27. The firm has a market capitalization of $14.55 billion, a price-to-earnings ratio of -37.98 and a beta of 1.48.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. bought a new stake in shares of Natera in the second quarter valued at about $28,000. Principal Securities Inc. bought a new stake in Natera during the fourth quarter worth about $32,000. GAMMA Investing LLC raised its holdings in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares in the last quarter. YHB Investment Advisors Inc. bought a new stake in Natera during the first quarter worth about $36,000. Finally, Oliver Lagore Vanvalin Investment Group raised its holdings in Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after acquiring an additional 389 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms recently commented on NTRA. Piper Sandler raised their target price on Natera from $120.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Jefferies Financial Group started coverage on Natera in a research report on Monday, June 3rd. They issued a “buy” rating and a $142.00 price objective for the company. Stephens reiterated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. Finally, Canaccord Genuity Group lifted their price objective on Natera from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, May 10th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $119.07.
View Our Latest Stock Report on NTRA
About Natera
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Read More
- Five stocks we like better than Natera
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Brinker International’s Price Dip is an Appetizing Entry Point
- 3 Warren Buffett Stocks to Buy Now
- 3 Stocks That Could Beat the September Blues
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.